Cerus Corporation (CERS)

NASDAQ: CERS · IEX Real-Time Price · USD
1.850
-0.080 (-4.15%)
At close: May 23, 2024, 4:00 PM
1.900
+0.050 (2.70%)
Pre-market: May 24, 2024, 8:33 AM EDT
-4.15%
Market Cap 342.05M
Revenue (ttm) 191.72M
Net Income (ttm) -31.56M
Shares Out 184.89M
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,109,213
Open 1.930
Previous Close 1.930
Day's Range 1.840 - 1.930
52-Week Range 1.210 - 3.080
Beta 1.31
Analysts Buy
Price Target 3.25 (+75.68%)
Earnings Date May 2, 2024

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jan 30, 1997
Employees 625
Stock Exchange NASDAQ
Ticker Symbol CERS
Full Company Profile

Financial Performance

In 2023, Cerus's revenue was $186.80 million, a decrease of -0.81% compared to the previous year's $188.32 million. Losses were -$37.49 million, -12.37% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3.25, which is an increase of 75.68% from the latest price.

Price Target
$3.25
(75.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 21st Annual Craig-Hallum Institu...

2 days ago - Business Wire

Cerus Corporation Announces First Quarter 2024 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total rev...

21 days ago - Business Wire

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock...

5 weeks ago - Business Wire

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet P...

2 months ago - Business Wire

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (...

2 months ago - Business Wire

Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-qua...

2 months ago - Business Wire

Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the cl...

3 months ago - Business Wire

Cerus Corporation to Participate in Upcoming Investor Conferences

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11th Annual MedTech, Dig...

4 months ago - Business Wire

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for full-...

4 months ago - Business Wire

Cerus Corporation Announces Third Quarter 2023 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total...

7 months ago - Business Wire

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

DALLAS--(BUSINESS WIRE)--Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today ...

7 months ago - Business Wire

Cerus Corporation to Release Third Quarter 2023 Financial Results on November 2, 2023

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the ...

7 months ago - Business Wire

Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from ...

8 months ago - Business Wire

Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will fo...

8 months ago - Business Wire

Cerus Corporation to Participate in the 2023 Cantor Global Healthcare Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus' chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Co...

9 months ago - Business Wire

Cerus Corporation Announces Second Quarter 2023 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total re...

10 months ago - Business Wire

Cerus Corporation to Release Second Quarter 2023 Financial Results on August 2, 2023

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the ...

11 months ago - Business Wire

Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33rd Regional International Society of Blood Transfusion (ISBT) ...

1 year ago - Business Wire

Cerus Corporation Celebrates World Blood Donor Day 2023

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023. In 2005, the World Health Assembly designated June 14 as World Bl...

1 year ago - Business Wire

Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U...

1 year ago - Business Wire

Cerus Corporation Announces First Quarter 2023 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total rev...

1 year ago - Business Wire

Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock...

1 year ago - Business Wire

Cerus Corporation Announces Record Fourth Quarter and Full-Year 2022 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the fourth quarter and full year ended December 31, 2022.

1 year ago - Business Wire

Cerus Corporation to Release Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after th...

1 year ago - Business Wire

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2022 Product Revenue and Provides Business Update

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for ful...

1 year ago - Business Wire